Lab
Inova Health Care Services
Inova Health Care Services was paid $6.82M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 17% of everything it billed.
33Billing provider infoINOVA HEALTH CARE SERVICES
FAIRFAX, VA 22031
FAIRFAX, VA 22031
33aNPI1437596855assigned 05/24/2013
33bProvider typeClinical Medical Laboratory
28Total paid$6.82M
24GClaims704,403
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#6 of 78
Median peer was paid$37K
This provider vs. median185×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official POPE, ALICE controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,093 | $130K | |
| 2019 | 68,742 | $377K | |
| 2020 | 81,963 | $1.11M | |
| 2021 | 122,056 | $1.59M | |
| 2022 | 134,041 | $1.32M | |
| 2023 | 130,915 | $1.17M | |
| 2024incomplete | 129,593 | $1.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 18,154 | 17,303 | $1.17M |
| 80061 | Lipid panel | 5.9% | 44,284 | 43,030 | $403K |
| 80053 | Comprehensive metabolic panel | 4.8% | 48,041 | 43,914 | $324K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.7% | 17,490 | 16,871 | $319K |
| 80050 | General health panel | 4.3% | 18,631 | 18,263 | $295K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.4% | 23,578 | 22,766 | $229K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.3% | 7,569 | 7,141 | $222K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.2% | 37,750 | 36,678 | $217K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.1% | 11,723 | 11,229 | $212K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 7,560 | 7,137 | $184K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 34,245 | 30,773 | $170K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.3% | 7,254 | 7,047 | $156K |
177 more codes
| 81514 | 2.1% | 1,374 | $144K | |
| 86803 | 2.0% | 11,365 | $139K | |
| 83013 | 2.0% | 2,310 | $135K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.9% | 4,433 | $129K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 91,271 | $105K |
| 82607 | 1.5% | 9,141 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 18,793 | $98K |
| 87481 | 1.4% | 3,578 | $96K | |
| 85027 | 1.4% | 22,344 | $95K | |
| 86235 | 1.1% | 1,340 | $78K | |
| 82728 | 1.1% | 8,459 | $77K | |
| 84439 | 1.1% | 12,478 | $77K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,409 | $68K |
| 86780 | <1% | 5,733 | $66K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,978 | $61K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,710 | $60K |
| 84153 | <1% | 4,197 | $53K | |
| 83970 | <1% | 1,882 | $51K | |
| 84403 | <1% | 2,264 | $50K | |
| 87340 | <1% | 5,609 | $47K | |
| 82570 | <1% | 12,534 | $47K | |
| 83550 | <1% | 8,015 | $47K | |
| 83540 | <1% | 8,516 | $37K | |
| 84481 | <1% | 3,363 | $36K | |
| 82043 | <1% | 11,014 | $34K | |
| 87081 | <1% | 5,808 | $32K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,368 | $31K |
| 86038 | <1% | 3,157 | $31K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,890 | $30K |
| 81001 | <1% | 12,617 | $29K | |
| 87799 | <1% | 2,525 | $27K | |
| 82746 | <1% | 2,541 | $26K | |
| 82670 | <1% | 997 | $25K | |
| 87077 | <1% | 4,427 | $25K | |
| 83880 | <1% | 901 | $24K | |
| 84146 | <1% | 1,420 | $24K | |
| 83001 | <1% | 1,409 | $23K | |
| 87186 | <1% | 3,799 | $21K | |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision | <1% | 833 | $21K |
| 87512 | <1% | 932 | $20K | |
| 83735 | <1% | 5,332 | $20K | |
| 81003 | <1% | 13,358 | $20K | |
| 84402 | <1% | 896 | $19K | |
| 86317 | <1% | 2,475 | $19K | |
| 86140 | <1% | 4,385 | $17K | |
| 82784 | <1% | 1,564 | $15K | |
| 83002 | <1% | 919 | $15K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 270 | $15K |
| 82627 | <1% | 774 | $15K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 1,130 | $15K |
| 88142 | <1% | 857 | $14K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 909 | $14K |
| 86376 | <1% | 1,132 | $13K | |
| 86696 | <1% | 1,012 | $13K | |
| 85610 | <1% | 5,957 | $13K | |
| 80076 | <1% | 1,683 | $11K | |
| 86200 | <1% | 1,082 | $11K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 391 | $11K |
| 85652 | <1% | 4,932 | $10K | |
| 86850 | <1% | 3,277 | $10K | |
| 86704 | <1% | 1,149 | $10K | |
| 82105 | <1% | 1,031 | $10K | |
| 80197 | <1% | 1,557 | $10K | |
| 86695 | <1% | 1,005 | $10K | |
| 86225 | <1% | 853 | $10K | |
| 83516 | <1% | 695 | $10K | |
| 87522 | Neg quan hep c or qual rna | <1% | 457 | $10K |
| 86800 | <1% | 828 | $9K | |
| 82533 | <1% | 688 | $9K | |
| 86431 | <1% | 1,747 | $8K | |
| 86480 | <1% | 2,383 | $8K | |
| 84550 | <1% | 2,400 | $8K | |
| 86762 | <1% | 1,007 | $8K | |
| 86900 | <1% | 3,423 | $8K | |
| 86901 | <1% | 3,417 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 392 | $7K |
| 80074 | <1% | 289 | $7K | |
| 84100 | <1% | 2,898 | $7K | |
| 87070 | <1% | 1,243 | $7K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 13,434 | $7K |
| 83655 | <1% | 541 | $6K | |
| 83690 | <1% | 1,136 | $6K | |
| 84702 | <1% | 1,576 | $6K | |
| 87497 | <1% | 372 | $6K | |
| 82550 | <1% | 1,035 | $5K | |
| 86039 | <1% | 550 | $5K | |
| 86160 | <1% | 330 | $5K | |
| 84425 | <1% | 748 | $5K | |
| 84480 | <1% | 440 | $5K | |
| 84156 | <1% | 1,669 | $5K | |
| 82248 | <1% | 1,029 | $4K | |
| 84445 | <1% | 311 | $4K | |
| 85730 | <1% | 1,541 | $4K | |
| 82950 | <1% | 807 | $3K | |
| 87563 | <1% | 199 | $3K | |
| 87205 | <1% | 1,119 | $3K | |
| 83615 | <1% | 785 | $3K | |
| 86708 | <1% | 305 | $3K | |
| 84630 | <1% | 308 | $3K | |
| 86787 | <1% | 417 | $3K | |
| 86334 | <1% | 195 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 52 | $3K |
| 82977 | <1% | 469 | $3K | |
| 86618 | <1% | 166 | $2K | |
| 80069 | <1% | 353 | $2K | |
| 84154 | <1% | 145 | $2K | |
| 84590 | <1% | 242 | $2K | |
| 86364 | <1% | 866 | $2K | |
| 82103 | <1% | 171 | $2K | |
| 82390 | <1% | 196 | $1K | |
| 84681 | <1% | 108 | $1K | |
| 82785 | <1% | 80 | $1K | |
| 83993 | <1% | 69 | $1K | |
| 82565 | <1% | 295 | $1K | |
| 86592 | <1% | 365 | $1K | |
| 83021 | <1% | 72 | $979.01 | |
| 82525 | <1% | 87 | $936.29 | |
| 85045 | <1% | 284 | $896.88 | |
| 84165 | <1% | 202 | $877.65 | |
| 87517 | <1% | 26 | $859.11 | |
| 36591 | <1% | 185 | $828.09 | |
| 87427 | <1% | 79 | $826.38 | |
| 87449 | <1% | 81 | $814.40 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 54 | $760.74 |
| 83519 | <1% | 75 | $721.70 | |
| 84460 | <1% | 167 | $680.48 | |
| 84207 | <1% | 26 | $652.20 | |
| 84432 | <1% | 84 | $645.99 | |
| 84270 | <1% | 28 | $593.19 | |
| 83520 | <1% | 62 | $562.45 | |
| 86769 | <1% | 36 | $558.86 | |
| 82610 | <1% | 45 | $526.25 | |
| 84450 | <1% | 128 | $495.76 | |
| 82310 | <1% | 136 | $447.31 | |
| 83498 | <1% | 16 | $421.15 | |
| 86735 | <1% | 39 | $420.18 | |
| 84144 | <1% | 30 | $414.78 | |
| 83921 | <1% | 26 | $398.69 | |
| 83721 | <1% | 195 | $386.41 | |
| 80503 | <1% | 62 | $381.16 | |
| 87209 | <1% | 24 | $370.64 | |
| 85007 | <1% | 121 | $337.20 | |
| 82040 | <1% | 122 | $336.94 | |
| 86003 | <1% | 17 | $330.43 | |
| 82374 | <1% | 117 | $323.90 | |
| 84295 | <1% | 125 | $323.07 | |
| 82378 | <1% | 24 | $316.65 | |
| 87338 | <1% | 113 | $312.29 | |
| 83020 | <1% | 22 | $309.98 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $308.80 |
| 86765 | <1% | 39 | $304.33 | |
| 82157 | <1% | 15 | $301.88 | |
| 82947 | <1% | 138 | $300.93 | |
| 82435 | <1% | 117 | $280.00 | |
| 82247 | <1% | 90 | $259.47 | |
| 87045 | <1% | 80 | $254.64 | |
| 84703 | <1% | 52 | $250.80 | |
| 84520 | <1% | 118 | $240.47 | |
| 86381 | <1% | 29 | $239.77 | |
| 86015 | <1% | 72 | $222.28 | |
| 84075 | <1% | 70 | $190.08 | |
| 87147 | <1% | 43 | $184.09 | |
| 83090 | <1% | 12 | $175.78 | |
| 85014 | <1% | 96 | $159.71 | |
| 87328 | <1% | 12 | $153.53 | |
| 82951 | <1% | 13 | $145.11 | |
| 82085 | <1% | 14 | $133.02 | |
| 84134 | <1% | 25 | $119.77 | |
| 83521 | <1% | 14 | $107.50 | |
| 87088 | <1% | 12 | $101.13 | |
| 87177 | <1% | 24 | $96.43 | |
| 85018 | <1% | 51 | $93.53 | |
| 84155 | <1% | 42 | $64.34 | |
| 83883 | <1% | 27 | $63.20 | |
| 85049 | <1% | 12 | $54.21 | |
| 85379 | <1% | 14 | $51.59 | |
| 82952 | <1% | 12 | $48.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOPE, ALICE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Inova Physician Partners, LLC | Chantilly, VA | $9.05M |
| Inova Health Care Services - Pathology | Falls Church, VA | $2.00M |
| Inova Health Care Services | Vienna, VA | $1.82M |
| Inova Ucc LLC | Vienna, VA | $968K |
| Inova Health Care Services | Dumfries, VA | $648K |
| Inova Health Care Services | Fairfax, VA | $339K |
| Inova Health Care Services | Falls Church, VA | $303K |
| Inova Health Care Services | Fairfax, VA | $239K |
| Inova Health Care Services | Waldorf, MD | $207K |
| Inova Cares - Community | Fairfax, VA | $45K |
| Inova Health Care Services | Fairfax, VA | $0.16 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.